Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Procter & Gamble heads into its October 13 print with the most consequential pre-earnings development coming not from short sellers or options traders, but from the analyst community.
The clearest signal heading into the print is a fresh upgrade from Evercore ISI. Robert Ottenstein moved P&G to Outperform from In-Line on October 6, lifting his target to $166 from $161, just four trading days before the report. That is a meaningful shift at a bellwether firm, and it arrives with the stock trading at $151.23, up 4.4% on the week and 3.9% on the month. RBC Capital kept its own Outperform rating on the same day but nudged its target down a dollar to $166, a signal that enthusiasm has limits rather than that conviction is fading. The broader consensus sits at Hold across 19 analysts, with 8 buyers and 11 neutrals, and a mean target of $160.78. That implies roughly 6% upside from current levels, modest for a name of this defensive pedigree.
Bulls point to volume recovery in Europe and Latin America and early signs of market-share improvement that could drive topline growth. Bears focus on the China problem: SK-II brand sales dropped 30% in Greater China, and US category growth rates fell 15% in December, suggesting the consumer backdrop remains uneven. TD Cowen reiterated Hold with a $150 target on September 30, essentially saying the stock is now fairly valued after its recent run. That view sits in tension with Evercore's upgrade, and the earnings report is where the disagreement gets resolved.
Short sellers have no firm view here. SI is barely above 1% of the free float at 24.4 million shares, essentially unchanged from the September 30 note. Borrow availability is essentially uncapped, with over 2.3 billion shares still available to lend. Cost to borrow has edged up to 0.42% from 0.14% a week ago, but that remains trivially low and the move looks like noise in a very thin lending market. Options positioning leans slightly more bullish than usual. The put/call ratio has eased to 0.69, just below its 20-day average of 0.70 and half a standard deviation on the call-heavy side, the opposite of defensive hedging. Retail attention is elevated, with Wikipedia traffic running more than two standard deviations above its 90-day norm as of late September, but that is a measure of interest rather than sentiment.
One ownership note worth flagging: The Vanguard Group's latest 13G/A filing, dated March 2026, shows its stake falling to 0%, down from 10.04% previously, while a separate Vanguard Capital Management entity holds 7.52%. This appears to reflect a reorganisation of Vanguard's internal structures rather than a genuine exit. Carry the standard caveat: 13D/G positions are as-last-disclosed around the 5% threshold, and a holder dropping below 5% need not file again.
The October 13 print is therefore less a test of whether P&G can grow and more a test of whether the China drag is stabilising and whether US category trends have bottomed at a level that justifies the stock's recent move back toward the upper end of its recent range.
See the live data behind this article on ORTEX.
Open PG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
